Suppression of HER-2 via siRNA interference promotes apoptosis and decreases metastatic potential of SKOV‑3 human ovarian carcinoma cells

Lu,Yan-Ming; Rong,Meng-Li; Shang,Chao; Wang,Ning; Li,Xiang; Zhao,Yan-Yan; Zhang,Shu-Lan

doi:10.3892/or.2012.2214

Suppression of HER-2 via siRNA interference promotes apoptosis and decreases metastatic potential of SKOV‑3 human ovarian carcinoma cells

Authors:
- Yan-Ming Lu
- Meng-Li Rong
- Chao Shang
- Ning Wang
- Xiang Li
- Yan-Yan Zhao
- Shu-Lan Zhang
View Affiliations

Affiliations: Department of Gynaecology and Obstetrics, The Affiliated Shengjing Hospital, China Medical University, Shenyang, P.R. China, Department of Neurobiology, China Medical University, Shenyang, P.R. China, Department of Clinical Genetics, Shengjing Hospital, China Medical University, Shenyang, P.R. China
Published online on: December 28, 2012 https://doi.org/10.3892/or.2012.2214
Pages: 1133-1139

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aberrant expression of human epidermal growth factor receptor-2 (HER-2) has been detected in ovarian cancer. However, the role of HER-2 in the development of ovarian cancer has not been sufficiently elucidated. The objective of this study was to determine the role of HER-2 in the apoptosis and metastasis of SKOV-3 ovarian cancer cells. SKOV-3 cells were transfected with three double‑stranded small interfering RNA (siRNA) molecules that target HER-2. Various sequences were synthesized by T7 transcription in vitro to select the most effective HER-2‑silencing siRNA. SKOV-3 cells were examined for growth inhibition using the MTT proliferation assay and apoptosis was assessed using flow cytometry and TUNEL assay. The Matrigel basement memebrane matrix was used to assess invasion and chemotactic mobility, as a model of tumor cell metastasis. Western blot analysis was used to detect the expression of matrix metallopeptidase-9 (MMP-9), E-cadherin, N-cadherin and vimentin. siRNA interference in HER-2 resulted in decreased cell proliferation and invasion and increased apoptosis. Western blot analysis demonstrated a marked increase in E-cadherin and MMP-9 and a reduction in N-cadherin and vimentin protein levels in the SKOV-3 cells. The suppression of HER-2 expression resulted in apoptosis and the inhibition of metastasis of SKOV-3 cells. Therefore, the overexpression of the HER-2 gene can enhance the metastatic potential of SKOV-3 cells by increasing the protein levels of MMP-9. Epithelial-mesenchymal transition may be involved in the HER-2 siRNA-induced invasion and migration of SKOV-3 cells. Taken together, these results suggest that HER-2 functions as an oncogene and may thus be an attractive therapeutic target in SKOV-3 ovarian cancer cells.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
2	Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar
3	Olayioye MA, Neve RM, Lane HA and Hynes NE: The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 19:3159–3167. 2000. View Article : Google Scholar : PubMed/NCBI
4	Baselga J and Arteaga CL: Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol. 23:2445–2459. 2005. View Article : Google Scholar : PubMed/NCBI
5	Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001. View Article : Google Scholar : PubMed/NCBI
6	Hynes NE and Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 5:341–354. 2005. View Article : Google Scholar : PubMed/NCBI
7	Duchnowska R, Biernat W, Szostakiewicz B, et al: Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2⁺ advanced breast cancer patients receiving trastuzumab-containing therapy. Oncologist. 17:26–35. 2012. View Article : Google Scholar : PubMed/NCBI
8	Howe LR and Brown PH: Targeting the HER/EGFR/ErbB family to prevent breast cancer. Cancer Prev Res. 4:1149–1157. 2011. View Article : Google Scholar : PubMed/NCBI
9	Modjtahedi H and Essapen S: Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs. 20:851–855. 2009. View Article : Google Scholar : PubMed/NCBI
10	Serrano-Olvera A, Dueñas-González A, Gallardo-Rincón D, Candelaria M and De la Garza-Salazar J: Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. Cancer Treat Rev. 32:180–190. 2006. View Article : Google Scholar : PubMed/NCBI
11	Rubin SC, Finstad CL, Wong GY, Almadrones L, Plante M and Lloyd KO: Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis. Am J Obstet Gynecol. 168:162–169. 1993. View Article : Google Scholar : PubMed/NCBI
12	Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE and Mello CC: Potent and specific genetic interference by stranded RNA in Caenorhabditis elegans. Nature. 391:806–811. 1998. View Article : Google Scholar
13	Szweykowska-Kulińska Z, Jarmołowski A and Figlerowicz M: RNA interference and its role in the regulation of eucaryotic gene expression. Acta Biochim Pol. 50:217–229. 2003.PubMed/NCBI
14	Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K and Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 411:494–498. 2001. View Article : Google Scholar : PubMed/NCBI
15	Ueno NT, Bartholomeusz C, Herrmann JL, et al: E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res. 6:250–259. 2000.PubMed/NCBI
16	Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
17	Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science. 267:1456–1462. 1995. View Article : Google Scholar : PubMed/NCBI
18	Chuang TC, Hsu SC, Cheng YT, Shao WS, Wu K, Fang GS, Ou CC and Wang V: Magnolol down-regulates HER2 gene expression, leading to inhibition of HER2-mediated metastatic potential in ovarian cancer cells. Cancer Lett. 311:11–19. 2011. View Article : Google Scholar : PubMed/NCBI
19	Yamashita-Kashima Y, Iijima S, Yorozu K, Furugaki K, Kurasawa M, Ohta M and Fujimoto-Ouchi K: Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin Cancer Res. 17:5060–5070. 2011. View Article : Google Scholar
20	Tanizaki J, Okamoto I, Fumita S, Okamoto W, Nishio K and Nakagawa K: Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification. Oncogene. 30:4097–4106. 2011. View Article : Google Scholar : PubMed/NCBI
21	Decock J, Thirkettle S, Wagstaff L and Edwards DR: Matrix metalloproteinases: protective roles in cancer. J Cell Mol Med. 15:1254–1265. 2011. View Article : Google Scholar : PubMed/NCBI
22	Hua H, Li M, Luo T, Yin Y and Jiang Y: Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cell Mol Life Sci. 68:3853–3868. 2011. View Article : Google Scholar : PubMed/NCBI
23	Luukkaa H, Klemi P, Leivo I, et al: Expression of matrix metalloproteinase-1, -7, -9, -13, Ki-67, and HER-2 in epithelial- myoepithelial salivary gland cancer. Head Neck. 32:1019–1027. 2010. View Article : Google Scholar : PubMed/NCBI
24	Kim IY, Yong HY, Kang KW and Moon A: Overexpression of ErbB2 induces invasion of MCF10A human breast epithelial cells via MMP-9. Cancer Lett. 275:227–233. 2009. View Article : Google Scholar : PubMed/NCBI
25	Tan M, Yao J and Yu D: Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res. 57:1199–1205. 1997.
26	Chua KN, Poon KL, Lim J, Sim WJ, Huang RY and Thiery JP: Target cell movement in tumor and cardiovascular diseases based on the epithelial-mesenchymal transition concept. Adv Drug Deliv Rev. 63:558–567. 2011. View Article : Google Scholar : PubMed/NCBI
27	Sethi S, Sarkar FH, Ahmed Q, et al: Molecular markers of epithelial-to-mesenchymal transition are associated with tumor aggressiveness in breast carcinoma. Transl Oncol. 4:222–226. 2011. View Article : Google Scholar : PubMed/NCBI
28	Jenndahl LE, Isakson P and Baeckström D: c-erbB2-induced epithelial-mesenchymal transition in mammary epithelial cells is suppressed by cell-cell contact and initiated prior to E-cadherin downregulation. Int J Oncol. 27:439–448. 2005.
29	Ricono JM, Huang M, Barnes LA, et al: Specific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis. Cancer Res. 69:1383–1391. 2009. View Article : Google Scholar : PubMed/NCBI
30	Ahmed N, Maines-Bandiera S, Quinn MA, Unger WG, Dedhar S and Auersperg N: Molecular pathways regulating EGF-induced epithelio-mesenchymal transition in human ovarian surface epithelium. Am J Physiol Cell Physiol. 290:C1532–C1542. 2006. View Article : Google Scholar
31	Fuchs BC, Fujii T, Dorfman JD, Goodwin JM, Zhu AX, Lanuti M and Tanabe KK: Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res. 68:2391–2399. 2008. View Article : Google Scholar
32	Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002. View Article : Google Scholar : PubMed/NCBI
33	Vergara D, Merlot B, Lucot JP, Collinet P, Vinatier D, Fournier I and Salzet M: Epithelial-mesenchymal transition in ovarian cancer. Cancer Lett. 291:59–66. 2010. View Article : Google Scholar : PubMed/NCBI
34	Lu YM, Zhang SL, Meng LR and Zhao YY: Influence of human epidermal growth factor receptor-2 siRNA on chemosensitivity to cisplatin of human ovarian carcinoma cells: an in vitro experiment. Zhonghua Yi Xue Za Zhi. 88:909–913. 2008.(In Chinese).
35	Abuharbeid S, Apel J, Zugmaier G, et al: Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells. Naunyn Schmiedebergs Arch Pharmacol. 371:141–151. 2005. View Article : Google Scholar : PubMed/NCBI